Neumora Therapeutics (NASDAQ:NMRA) Cut to "Hold" at Stifel Nicolaus

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating in a note issued to investors on Friday, Marketbeat Ratings reports. They presently have a $2.00 price objective on the stock, down from their prior price objective of $6.00. Stifel Nicolaus' price objective suggests a potential upside of 39.86% from the stock's current price.

A number of other analysts also recently commented on NMRA. Bank of America decreased their target price on Neumora Therapeutics from $22.00 to $7.00 and set a "buy" rating on the stock in a research report on Monday, January 6th. Needham & Company LLC reissued a "buy" rating and issued a $5.00 price objective on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. William Blair restated an "outperform" rating on shares of Neumora Therapeutics in a report on Wednesday, January 15th. HC Wainwright dropped their price objective on shares of Neumora Therapeutics from $30.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Finally, Royal Bank of Canada restated a "sector perform" rating and issued a $4.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Neumora Therapeutics currently has a consensus rating of "Hold" and an average target price of $10.14.

Remove Ads

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock traded up $0.09 during trading hours on Friday, reaching $1.43. 1,227,622 shares of the stock were exchanged, compared to its average volume of 1,422,371. The firm's 50 day moving average is $2.24 and its 200 day moving average is $8.52. The stock has a market cap of $231.63 million, a P/E ratio of -0.76 and a beta of 2.59. Neumora Therapeutics has a 52-week low of $1.26 and a 52-week high of $18.61.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.46) by $0.09. Equities research analysts expect that Neumora Therapeutics will post -1.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in shares of Neumora Therapeutics by 54.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company's stock valued at $26,159,000 after buying an additional 694,385 shares during the last quarter. Barclays PLC lifted its holdings in shares of Neumora Therapeutics by 352.9% in the 3rd quarter. Barclays PLC now owns 129,210 shares of the company's stock worth $1,708,000 after purchasing an additional 100,678 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Neumora Therapeutics by 139.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 698,255 shares of the company's stock worth $9,224,000 after buying an additional 406,891 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Neumora Therapeutics in the third quarter valued at $1,097,000. Finally, Wexford Capital LP lifted its stake in Neumora Therapeutics by 90.1% in the third quarter. Wexford Capital LP now owns 217,879 shares of the company's stock valued at $2,878,000 after buying an additional 103,285 shares during the last quarter. Institutional investors own 47.65% of the company's stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.